Patent attributes
An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.
